Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-Label Safety Extension Study of Olesoxime (TRO19622) in ALS Patients Treated With Riluzole
2010-021179-10Phase 2Terminated
- Sponsor
- Trophos
- Start
- Nov 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of olesoxime in amyotrophic lateral sclerosis (ALS), sponsored by Trophos. Primary endpoint: Primary safety assessment of olesoxime. Started Nov 2010; status: terminated.
02
Drugs
olesoxime
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on 2010-021179-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-021179-10.